|
PABPC4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.54109999708874E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.35990005315045E-09 |
| Normal-vs-Stage2 |
2.721000E-01 |
| Normal-vs-Stage3 |
4.40889999999694E-05 |
| Normal-vs-Stage4 |
1.71349999966708E-07 |
| Stage1-vs-Stage2 |
9.301200E-03 |
| Stage1-vs-Stage3 |
3.521600E-01 |
| Stage1-vs-Stage4 |
1.433780E-01 |
| Stage2-vs-Stage3 |
8.022300E-02 |
| Stage2-vs-Stage4 |
2.461100E-03 |
| Stage3-vs-Stage4 |
4.498000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.74159994495938E-09 |
| Normal-vs-AfricanAmerican |
3.383000E-04 |
| Normal-vs-Asian |
2.44699999996101E-06 |
| Caucasian-vs-AfricanAmerican |
4.192800E-01 |
| Caucasian-vs-Asian |
1.071370E-01 |
| AfricanAmerican-vs-Asian |
7.221600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.46029999706465E-08 |
| Normal-vs-Female |
4.64620000251159E-08 |
| Male-vs-Female |
1.647770E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.26900001617969E-09 |
| Normal-vs-Age(41-60Yrs) |
8.16679999959824E-07 |
| Normal-vs-Age(61-80Yrs) |
1.225990E-04 |
| Normal-vs-Age(81-100Yrs) |
1.275370E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.092400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.434960E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.893200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.231600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.594200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.309200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.338800E-01 |
| Classical-VS-Follicular |
5.63210034165706E-10 |
| Classical-VS-Other |
8.601800E-01 |
| Classical-VS-Normal |
3.04389846661479E-12 |
| Tall-VS-Follicular |
2.393100E-04 |
| Tall-VS-Other |
9.471400E-01 |
| Tall-VS-Normal |
4.09009999999821E-05 |
| Follicular-VS-Other |
3.717900E-02 |
| Follicular-VS-Normal |
8.789200E-01 |
| Other-VS-Normal |
4.960400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.613700E-04 |
| Normal-vs-N1 |
2.010600E-04 |
| N0-vs-N1 |
2.012800E-01 |
|
|
